Matching-adjusted indirect comparison in Chinese patients with plaque psoriasis (xeligekimab trial n=281): week-12 PASI 75 was similar to secukinumab (93.0% vs 97.7%, p=0.052); week-52 PASI 100 was higher (57.8% vs 42.1%). Hypothesis-generating.
RCTn = 281
Ding et al. Efficacy and Safety of Xeligekimab Compared to Other IL-17A Inhibitors for Chinese Patients with Moderate-to-severe Plaque Psoriasis: A Matching-adjusted Indirect Comparisons